Aerospace Group:

Homeland Security

DoD Awards Morphotek $2.3M to Develop Biowarfare Therapies

DDN

Wednesday, October 3rd, 2007

SHARE:

Morphotek, Inc., a subsidiary of Japanese pharmaceutical company Eisai Co., received $2.3 million in funding from the Department of Defense to support the development of biologic- based monoclonal antibody therapies against biowarfare agents. Under the nine-month contract Morphotek will continue developing the therapies to treat Botulinum neurotoxins. "The further development of these compounds will enable us to advance these leads into clinical studies for validation and registration," says Nicholas Nicolaides, president and CEO of Morphotek.

Congress

Munitions Fired Represent Most of $25 Billion Spent By Pentagon on Iran War So Far

Munitions fired in the two-month old “Operation Epic Fury” against Iran represent most of the $25 billion cost the Pentagon has incurred thus far in the conflict, the acting Defense […]

Congress

Slotkin: Pentagon Should Use Anthropic’s Mythos To Spot Cyber Security Gaps

The Pentagon should be using Anthropic‘s recently announced Mythos artificial intelligence model to spot gaps in cyber security, Sen. Elissa Slotkin (D-Mich.) said on Tuesda. “I think the thing that […]

Budd And Shaheen Bill Would Authorize 329 F-15EX Fighters

Two members of the Senate Armed Services Committee (SASC), Sen. Ted Budd (R-N.C.) and Sen. Jeanne Shaheen (D-N.H.), have introduced the Airpower Acceleration Act, which would authorize multi-year procurements of […]

Congress

HASC’s Wittman Sees ‘Challenging’ Push For $350B In Reconciliation Funds, Wants Sustained Defense Increase

NATIONAL HARBOR, Md.– Congress’ work to pass $350 billion in reconciliation funds to support the Trump administration’s push for a $1.5 trillion fiscal year 2027 defense topline is “going to […]